Table 1.
The AChE inhibitors now available or unavailable on the market for clinical use in AD.
| AChE Inhibitor | Dosage (mg/d) |
Outcomes and Side Effects | Availability for Clinical Use | Reference |
|---|---|---|---|---|
| Tacrine | 80–160 | Nausea and abnormal liver functionality | No | [10] |
| Physostigmine | 36 | Nausea, diarrhea, and dizziness | No | [11] |
| Rivastigmine | 6–12 | Nausea, vomiting, and diarrhea | Yes | [11] |
| Galantamine * | 20–50 | Nausea, vomiting, and diarrhea | Yes | [11] |
| Donepezil | 10 | Higher cognitive improvements and reduced inflammatory cytokines as well as oxidative stress | Yes | [12] |
| 5 | Reduced inflammatory cytokines and oxidative stress | |||
| Metrifonate | NA | Bradycardia, rhinitis, abdominal pain, neuromuscular dysfunction, and respiratory failure | No | [13] |
* Fewer side effects compared to other AChE inhibitor drugs; NA, not available.